Preclinical services from a top pre-clinical Contract Research Organization in Kiev, UA.
Our organization is an independent Contract Research Organization based in the United States that provides preclinical drug testing in top-notch, GLP certified research laboratories in Eastern Europe. Our testing facilities are overseen by the UNAMS and Ministry of Health and offer services for commercial development of new drug discoveries as part of their core purpose. Our company was founded to offer the top-notch, low-cost services of these laboratories to start-up bio-tech companies in the U.S. and Europe, thereby providing them with a smart option for advancing development programs rapidly and at much lower cost than other commercial Contract Research Organizations. We offer a broad range of preclinical CRO including drug safety, acute and chronic toxicity, pharmacological screening, bioavailability, bioequivalence, and complete in vitro and in vivo screening for anticancer activity.
Our preclinical CRO is able to price pre-clinical toxicology far below other Contract Research Organizations because we have a very low overhead in the U.S. and conduct all trials in Ukraine where labor and laboratory costs are much lower. Our team in the United States is comprised of only of the company principals who work directly with customers; we have no marketing expenses aside from our web site, and no central offices, administrative staff or other overhead to increase costs. We have much lower trials conduct costs in Ukraine due to much lower personnel rates and are happy to provide our most attractive pricing for longer and more complex preclinical tests where labor is the greatest part of the overall price. Since we use the same stable international suppliers for lab animals, reagents and laboratory supplies as other CROs, we have no cost advantage on these materials and thus less overall cost savings for very short-term pre-clinical tests. But, regardless of your study protocol and length, our goal is to provide our clients the greatest possible value for their investment.